Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations
Autore:
Bush, LM; Johnson, CC;
Indirizzi:
Med Coll Penn & Hahnemann Univ, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ Philadelphia PA USA 19129 ia, PA 19129 USA John F Kennedy Mem Med Ctr, Div Infect Dis, W Palm Beach, FL USA John F Kennedy Mem Med Ctr W Palm Beach FL USA Dis, W Palm Beach, FL USA Dept Publ Hlth, Philadelphia, PA USA Dept Publ Hlth Philadelphia PA USADept Publ Hlth, Philadelphia, PA USA
Titolo Testata:
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
fascicolo: 2, volume: 14, anno: 2000,
pagine: 409 -
SICI:
0891-5520(200006)14:2<409:UABIC>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
PENICILLIN-BINDING PROTEINS; PLUS CLAVULANIC ACID; GRANULOCYTOPENIC CANCER-PATIENTS; RESPIRATORY-TRACT INFECTION; BACTEROIDES-FRAGILIS GROUP; INTENSIVE-CARE UNITS; PIPERACILLIN-TAZOBACTAM; PSEUDOMONAS-AERUGINOSA; INVITRO ACTIVITY; AMPICILLIN-SULBACTAM;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
128
Recensione:
Indirizzi per estratti:
Indirizzo: Johnson, CC Med Coll Penn & Hahnemann Univ, Sch Med, Dept Med, Div Infect Dis, 3300 Henry Ave, Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ 3300 Henry Ave Philadelphia PA USA 19129
Citazione:
L.M. Bush e C.C. Johnson, "Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations", INF DIS CL, 14(2), 2000, pp. 409

Abstract

The last penicillin to be made available for clinical use in the United States was the combination drug piperacillin-tazobactam. Since approval of this agent by the Food and Drug Administration (FDA) in 1993, research on newpenicillins and new indications for older penicillins has been limited. The lack of recent developments in the penicillin class of antimicrobial agents, however, neither diminishes their historical significance in the battleagainst infectious diseases nor their continued importance as safe and effective therapeutic agents. Penicillin, the prototype beta-lactam antibiotic, was first isolated from Penicillium notatum by Dr. Alexander Fleming in 1929. Because of difficulties in production and purification, the drug was not available for clinical use until 1941 when it was proven effective for the treatment of streptococcal and gonococcal infections. Subsequently, the evolution and spread of penicillin-resistant organisms along with the need to increase the antimicrobial spectrum of activity of penicillin led to the development of other beta-lactam antibiotics. Most of these were formulated by manipulating the basic penicillin molecule to result in agents with desirable new antimicrobial and pharmacologic properties. Alternatively, existing penicillins were combined with additional compounds that afforded specific protection from hydrolysis by beta-lactamases. This article reviews only the most recent additions to the formulary of penicillins, the ureidopenicillins, and combinationsof penicillins with beta-lactamase inhibitors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 00:07:27